Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Forde PM, Chaft JE, Pardoll DM.

N Engl J Med. 2018 Aug 30;379(9):e14. doi: 10.1056/NEJMc1808251. No abstract available.

PMID:
30157404
2.

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Lommatzsch M, Bratke K, Stoll P.

N Engl J Med. 2018 Aug 30;379(9):e14. doi: 10.1056/NEJMc1808251. No abstract available.

PMID:
30179396
3.

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Yang X, Yin R, Xu L.

N Engl J Med. 2018 Aug 30;379(9):e14. doi: 10.1056/NEJMc1808251. No abstract available.

PMID:
30179394
4.

Neoadjuvant PD-1 blockade in NSCLC.

Killock D.

Nat Rev Clin Oncol. 2018 Jul;15(7):404. doi: 10.1038/s41571-018-0032-0. No abstract available.

PMID:
29700379
5.

Neoadjuvant Nivolumab Checks Lung Cancer.

[No authors listed]

Cancer Discov. 2018 Jun;8(6):667-668. doi: 10.1158/2159-8290.CD-NB2018-049. Epub 2018 Apr 16.

6.

Understanding patterns of pathologic response following neoadjuvant immunotherapy for solid tumors.

Sholl LM.

Ann Oncol. 2018 Aug 1;29(8):1630-1632. doi: 10.1093/annonc/mdy227. No abstract available.

PMID:
30052725
7.

PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.

Bagley SJ, Bauml JM, Langer CJ.

Clin Adv Hematol Oncol. 2015 Oct;13(10):676-83. Review.

PMID:
27058572
8.

Neoadjuvant versus adjuvant therapy for resectable non-small-cell lung cancer.

Belani CP.

Clin Lung Cancer. 2004 Jul;6(1):8. No abstract available.

PMID:
15310410
9.

Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?

Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M, Giles FJ.

Clin Lung Cancer. 2016 Sep;17(5):350-361. doi: 10.1016/j.cllc.2016.03.011. Epub 2016 Apr 6. Review.

PMID:
27137346
10.

PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?

Tanvetyanon T, Gray JE, Antonia SJ.

Expert Opin Biol Ther. 2017 Mar;17(3):305-312. doi: 10.1080/14712598.2017.1280454. Epub 2017 Jan 18. Review.

PMID:
28064556
11.

Neoadjuvant therapy for marginally resectable (clinical N2), non-small cell lung cancer. American College of Radiology. ACR Appropriateness Criteria.

Byhardt RW, Sause WT, Curran WJ Jr, Fuller D, Graham MV, Ko B, Komaki R, Weisenburger TH, Kaiser LR, Leibel SA, Choi NC.

Radiology. 2000 Jun;215 Suppl:1331-45. No abstract available.

PMID:
11037550
12.

PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.

Takamori S, Takada K, Toyokawa G, Azuma K, Shimokawa M, Jogo T, Yamada Y, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Anticancer Res. 2018 Oct;38(10):5897-5901. doi: 10.21873/anticanres.12933.

PMID:
30275216
13.

Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).

Kocher F, Pircher A, Mohn-Staudner A, Romeder F, Duller W, Steinmaurer M, Eckmayr J, Schmid T, Hilbe W, Fiegl M, Greil R.

Lung Cancer. 2014 Sep;85(3):395-400. doi: 10.1016/j.lungcan.2014.06.019. Epub 2014 Jul 3.

PMID:
25043642
14.

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.

Hellmann MD, Chaft JE, William WN Jr, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG; University of Texas MD Anderson Lung Cancer Collaborative Group.

Lancet Oncol. 2014 Jan;15(1):e42-50. doi: 10.1016/S1470-2045(13)70334-6. Review.

15.

Neoadjuvant chemotherapy for resectable non-small-cell lung cancer.

Gray J, Sommers E, Alvelo-Rivera M, Robinson L, Bepler G.

Oncology (Williston Park). 2009 Sep;23(10):879-86. Review.

16.

Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.

Sui H, Ma N, Wang Y, Li H, Liu X, Su Y, Yang J.

J Immunol Res. 2018 Aug 8;2018:6984948. doi: 10.1155/2018/6984948. eCollection 2018. Review.

17.

Neoadjuvant Therapy in Non-Small Cell Lung Cancer.

Zheng Y, Jaklitsch MT, Bueno R.

Surg Oncol Clin N Am. 2016 Jul;25(3):567-84. doi: 10.1016/j.soc.2016.02.010. Review.

PMID:
27261916
18.

Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma.

Song Z, Yu X, Zhang Y.

Lung Cancer. 2016 Sep;99:166-71. doi: 10.1016/j.lungcan.2016.07.013. Epub 2016 Jul 15.

PMID:
27565935
19.

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.

Gillen S, Schuster T, Meyer Zum B├╝schenfelde C, Friess H, Kleeff J.

PLoS Med. 2010 Apr 20;7(4):e1000267. doi: 10.1371/journal.pmed.1000267. Review.

20.

Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.

Zhang P, Ma Y, Lv C, Huang M, Li M, Dong B, Liu X, An G, Zhang W, Zhang J, Zhang L, Zhang S, Yang Y.

Cancer Sci. 2016 Nov;107(11):1563-1571. doi: 10.1111/cas.13072.

Supplemental Content

Support Center